GE Healthcare Life Sciences is now Cytiva - Find out more

January 21, 2020

GE Healthcare Life Sciences plans new manufacturing facility in Switzerland

By GE Healthcare Life Sciences

GE Healthcare Life Sciences is building a new 7,360 square meter facility in Grens, Switzerland, in the new Signy Park, for the manufacture of single use kits for the Sepax and Sefia cell processing systems. The facility will meet global regulatory requirements and is expected to be fully operational in 2022.


GE Healthcare Life Sciences is building a new 7,360 square meter facility in Grens, Switzerland, in the new Signy Park, for the manufacture of single use kits for the Sepax and Sefia cell processing systems. The facility will meet global regulatory requirements and is expected to be fully operational in 2022.

Nemaco, a Dutch-Swiss based developer that specializes in the realization of made-to-measure buildings for multinational corporations, will design and build the new facility. It will be customized to meet specific business needs and will be able to scale with industry growth.

In addition to its manufacturing capabilities, the new site will house a Center of Excellence that will feature advanced cell and gene therapy manufacturing facilities and will also serve as a base for European customer trainings and educational initiatives. The site will also support a growing Research & Development team and other subject matter experts.

The new facility will be able to house up to 200 employees.

Emmanuel Ligner, President & CEO, GE Healthcare Life Sciences, said: “With more than 900 regenerative companies worldwide, we see increased demand for our resources and expertise. Our Swiss operations are critical to the success of our cell and gene therapy customers, so this new facility will allow us to accelerate capacity and provide a single location where our research, engineering and service teams can thrive. Plus, we will be able to attract the region’s top talent.”

Catarina Flyborg, General Manager, Cell and Gene Therapy, GE Healthcare Life Sciences, said: “From clinical trials to commercialization, regenerative medicine is going to transform global healthcare. This new facility will allow us to meet anticipated global demand while simultaneously developing the next generation of products that will accelerate the commercialization and industrialization of cell and gene therapies.”

Rembert Berg, Chairman, Nemaco Group, said: “We are honored to start with the development of GE Healthcare Life Sciences’ new manufacturing facility in Signy Park, as the first and key long-term occupier for the Park.”

The new site will complement GE Healthcare Life Sciences global network of manufacturing facilities in the US, UK, Sweden and China.

About GE Healthcare Life Sciences

GE Healthcare Life Sciences helps therapy innovators, researchers and healthcare providers accelerate how precision diagnostics and therapies are invented, made and used. Our products enable biological analysis, research, development and the manufacture of advanced therapies and vaccines. Life Sciences is part of the $19.8 billion healthcare business of GE (NYSE: GE). With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, GE Healthcare helps efficiently improve outcomes for patients, healthcare providers, researchers, and life sciences companies around the world. Visit our website https://www.gelifesciences.com/about-us for more information.

Media Contacts

Colleen Connolly
GE Healthcare Life Sciences
Colleen.Connolly@ge.com
+774 245 3893

Julie Vincent
Nemaco Suisse SA
jv@nemaco.ch
+41 22 362 06 11